Diagnostic and prognostic use of bone turnover markers

Recent Results in Cancer Research

Volumn 192, Issue , 2012, Pages 197-223

  Joerger, Markus ^a   Huober, Jens ^a  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL PROPEPTIDE OF PROCOLLAGEN TYPE 1; AMINO TERMINAL TELOPEPTIDE; BONE SIALOPROTEIN; CARBOXY TERMINAL TELOPEPTIDE; DEOXYPYRIDINOLINE; DICKKOPF 1 PROTEIN; MOLECULAR MARKER; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROSTATE SPECIFIC ANTIGEN; PYRIDINOLINE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TARTRATE RESISTANT ACID PHOSPHATASE TYPE 5B; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ARTICLE; BONE DEVELOPMENT; BONE MATRIX; BONE METASTASIS; BONE TURNOVER; BREAST CANCER; CANCER CELL; CANCER DIAGNOSIS; CANCER RELAPSE; CELL MIGRATION; DIAGNOSTIC VALUE; EARLY CANCER; EARLY DIAGNOSIS; HUMAN; LUNG NON SMALL CELL CANCER; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN URINE LEVEL; SENSITIVITY AND SPECIFICITY;

EID: 84858187351     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-21892-7_10     Document Type: Article

References (88)

1. Abildgaard N, Rungby J, Glerup H, Brixen K, Kassem M, Brincker H, Heickendorff L, Eriksen EF, Nielsen JL (1998) Long-term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma. Eur J Haematol 61:128-134 (Pubitemid 28352615)
2. Ali SM, Demers LM, Leitzel K, Harvey HA, Clemens D, Mallinak N, Engle L, Chinchilli V, Costa L, Brady C, Seaman J, Lipton A (2004) Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis. Ann Oncol 15:455-459 (Pubitemid 38444549)
3. Aruga A, Koizumi M, Hotta R, Takahashi S, Ogata E (1997) Usefulness of bone metabolic markers in the diagnosis and follow-up of bone metastasis from lung cancer. Br J Cancer 76:760-764 (Pubitemid 27379743)
4. Bataille R, Delmas PD, Chappard D, Sany J (1990) Abnormal serum bone Gla protein levels in multiple myeloma. Crucial role of bone formation and prognostic implications. Cancer 66:167-172 (Pubitemid 20197103)
5. Bauer DC, Garnero P, Hochberg MC, Santora A, Delmas P, Ewing SK, Black DM (2006) Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res 21:292-299 (Pubitemid 43265295)
6. Bellahcene A, Menard S, Bufalino R, Moreau L, Castronovo V (1996) Expression of bone sialoprotein in primary human breast cancer is associated with poor survival. Int J Cancer 69:350-353 (Pubitemid 26298303)
7. Bellahcene A, Maloujahmoum N, Fisher LW, Pastorino H, Tagliabue E, Menard S, Castronovo V (1997) Expression of bone sialoprotein in human lung cancer. Calcif Tissue Int 61:183-188 (Pubitemid 27360809)
8. Brasso K, Christensen IJ, Johansen JS, Teisner B, Garnero P, Price PA, Iversen P (2006) Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma. Prostate 66:503-513
9. Brown JM, Vessella RL, Kostenuik PJ, Dunstan CR, Lange PH, Corey E (2001) Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. Clin Cancer Res 7:2977-2983 (Pubitemid 32963814)
10. Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, Lee KA, Zheng M, Hei YJ, Coleman RE (2005) Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97:59-69
11. Caillot-Augusseau A, Lafage-Proust MH, Soler C, Pernod J, Dubois F, Alexandre C (1998) Bone formation and resorption biological markers in cosmonauts during and after a 180-day space flight (Euromir 95). Clin Chem 44:578-585 (Pubitemid 28141355)
12. Calvo MS, Eyre DR, Gundberg CM (1996) Molecular basis and clinical application of biological markers of bone turnover. Endocr Rev 17:333-368 (Pubitemid 26277979)
13. Capeller B, Caffier H, Sutterlin MW, Dietl J (2003) Evaluation of tartrate-resistant acid phosphatase (TRAP) 5b as serum marker of bone metastases in human breast cancer. Anticancer Res 23:1011-1015 (Pubitemid 36750912)
14. Carlson K, Larsson A, Simonsson B, Turesson I, Westin J, Ljunghall S (1999) Evaluation of bone disease in multiple myeloma: a comparison between the resorption markers urinary deoxypyridinoline/creatinine (DPD) and serum ICTP, and an evaluation of the DPD/osteocalcin and ICTP/osteocalcin ratios. Eur J Haematol 62:300-306 (Pubitemid 29232256)
15. Chao TY, Ho CL, Lee SH, Chen MM, Janckila A, Yam LT (2004) Tartrate-resistant acid phosphatase 5b as a serum marker of bone metastasis in breast cancer patients. J Biomed Sci 11:511-516 (Pubitemid 38721035)
16. Chung JH, Park MS, Kim YS, Chang J, Kim JH, Kim SK (2005) Usefulness of bone metabolic markers in the diagnosis of bone metastasis from lung cancer. Yonsei Med J 46:388-393 (Pubitemid 40959880)
17. Coleman RE (2002) The clinical use of bone resorption markers in patients with malignant bone disease. Cancer 94:2521-2533 (Pubitemid 34478064)
18. Coleman J, Brown E, Terpos A, Lipton MR, Smith R, Cook P (2008) Major, bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev 34:629-639
19. Costa L, Demers LM, Gouveia-Oliveira A, Schaller J, Costa EB, de Moura MC, Lipton A (2002) Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol 20:850-856 (Pubitemid 34111395)
20. Dane F, Turk HM, Sevinc A, Buyukberber S, Camci C, Tarakcioglu M (2008) Markers of bone turnover in patients with lung cancer. J Natl Med Assoc 100:425-428 (Pubitemid 351556503)
21. De Pinieux G, Flam T, Zerbib M, Taupin P, Bellahcene A, Waltregny D, Vieillefond A, Poupon MF (2001) Bone sialoprotein, bone morphogenetic protein 6 and thymidine phosphorylase expression in localized human prostatic adenocarcinoma as predictors of clinical outcome: a clinicopathological and immunohistochemical study of 43 cases. J Urol 166:1924-1930 (Pubitemid 32953459)
22. Diel IJ, Solomayer EF, Seibel MJ, Pfeilschifter J, Maisenbacher H, Gollan C, Pecherstorfer M, Conradi R, Kehr G, Boehm E, Armbruster FP, Bastert G (1999) Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis. Clin Cancer Res 5:3914-3919 (Pubitemid 30013765)
23. Ebert W, Muley T, Herb KP, Schmidt-Gayk H (2004) Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients. Anticancer Res 24:3193-3201 (Pubitemid 39390972)
24. Ek-Rylander B, Flores M, Wendel M, Heinegard D, Andersson G (1994) Dephosphorylation of osteopontin and bone sialoprotein by osteoclastic tartrate-resistant acid phosphatase. Modulation of osteoclast adhesion in vitro. J Biol Chem 269:14853-14856
25. Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW (2001) Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 7:4060-4066 (Pubitemid 34044628)
26. Fisher LW, Fedarko NS (2003) Six genes expressed in bones and teeth encode the current members of the SIBLING family of proteins. Connect Tissue Res 44(Suppl 1):33-40 (Pubitemid 36395419)
27. Fisher LW, Jain A, Tayback M, Fedarko NS (2004) Small integrin binding ligand N-linked glycoprotein gene family expression in different cancers. Clin Cancer Res 10:8501-8511 (Pubitemid 40053416)
28. Fonseca R, Trendle MC, Leong T, Kyle RA, Oken MM, Kay NE, Van Ness B, Greipp PR (2000) Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients. Br J Haematol 109:24-29 (Pubitemid 30340575)
29. Guang-da X, Hui-ling S, Zhi-song C, Lin-shuang Z (2005) Changes in plasma concentrations of osteoprotegerin before and after levothyroxine replacement therapy in hypothyroid patients. J Clin Endocrinol Metab 90:5765-5768
30. Heuck C, Wolthers OD (1998) A placebo-controlled study of three osteocalcin assays for assessment of prednisolone-induced suppression of bone turnover. J Endocrinol 159:127-131 (Pubitemid 28459275)
31. Ikeda I, Miura T, Kondo I (1996) Pyridinium cross-links as urinary markers of bone metastases in patients with prostate cancer. Br J Urol 77:102-106
32. Ivaska KK, Pettersson K, Nenonen A, Uusi-Rasi K, Heinonen A, Kannus P, Vaananen HK (2005) Urinary osteocalcin is a useful marker for monitoring the effect of alendronate therapy. Clin Chem 51:2362-2365 (Pubitemid 41692584)
33. Jain A, Karadag A, Fohr B, Fisher LW, Fedarko NS (2002) Three SIBLINGs (small integrin-binding ligand, N-linked glycoproteins) enhance factor H's cofactor activity enabling MCP-like cellular evasion of complement-mediated attack. J Biol Chem 277:13700-13708 (Pubitemid 34967971)
34. Jones DH, Nakashima T, Sanchez OH, Kozieradzki I, Komarova SV, Sarosi I, Morony S, Rubin E, Sarao R, Hojilla CV, Komnenovic V, Kong YY, Schreiber M, Dixon SJ, Sims SM, Khokha R, Wada T, Penninger JM (2006) Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440:692-696
35. Jukkola A, Bloigu R, Holli K, Joensuu H, Valavaara R, Risteli J, Blanco G (2001) Postoperative PINP in serum reflects metastatic potential and poor survival in node-positive breast cancer. Anticancer Res 21:2873-2876 (Pubitemid 33051144)
36. Jung K, Lein M, von Hosslin K, Brux B, Schnorr D, Loening SA, Sinha P (2001) Osteoprotegerin in serum as a novel marker of bone metastatic spread in prostate cancer. Clin Chem 47:2061-2063 (Pubitemid 33010733)
37. Jung K, Stephan C, Semjonow A, Lein M, Schnorr D, Loening SA (2003) Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer. J Urol 170:2302-2305 (Pubitemid 37413980)
38. Jung K, Lein M, Stephan C, Von Hosslin K, Semjonow A, Sinha P, Loening SA, Schnorr D (2004) Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer 111:783-791 (Pubitemid 39062904)
39. Jung K, Lein M, Ringsdorf M, Roigas J, Schnorr D, Loening SA, Staack A (2006) Diagnostic and prognostic validity of serum bone turnover markers in metastatic renal cell carcinoma. J Urol 176:1326-1331 (Pubitemid 44307214)
40. Karadag A, Ogbureke KU, Fedarko NS, Fisher LW (2004) Bone sialoprotein, matrix metalloproteinase 2, and alpha(v)beta3 integrin in osteotropic cancer cell invasion. J Natl Cancer Inst 96:956-965 (Pubitemid 38868142)
41. Karapanagiotou EM, Terpos E, Dilana KD, Alamara C, Gkiozos I, Polyzos A, Syrigos KN (2010) Serum bone turnover markers may be involved in the metastatic potential of lung cancer patients. Med Oncol 27:332-338
42. Keskikuru R, Kataja V, Kosma VM, Eskelinen M, Uusitupa M, Johansson R, Risteli L, Risteli J, Jukkola A (1999) Preoperative high type I collagen degradation marker ICTP reflects advanced breast cancer. Anticancer Res 19:4481-4484 (Pubitemid 30042810)
43. Koizumi M, Yonese J, Fukui I, Ogata E (2001) The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone. BJU Int 87:348-351 (Pubitemid 32240847)
44. Koizumi M, Takahashi S, Ogata E (2003) Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis. Anticancer Res 23:4095-4099 (Pubitemid 37474903)
45. Kong QQ, Sun TW, Dou QY, Li F, Tang Q, Pei FX, Tu CQ, Chen ZQ (2007) Beta-CTX and ICTP act as indicators of skeletal metastasis status in male patients with non-small cell lung cancer. Int J Biol Markers 22:214-220 (Pubitemid 350081631)
46. Koopmans N, de Jong IJ, Breeuwsma AJ, van der Veer E (2007) Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach. J Urol 178:849-853 discussion 853; quiz 1129 (Pubitemid 47211070)
47. Korpela J, Tiitinen SL, Hiekkanen H, Halleen JM, Selander KS, Vaananen HK, Suominen P, Helenius H, Salminen E (2006) Serum TRACP 5b and ICTP as markers of bone metastases in breast cancer. Anticancer Res 26:3127-3132 (Pubitemid 44161811)
48. Leeming DJ, Koizumi M, Byrjalsen I, Li B, Qvist P, Tanko LB (2006) The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients. Cancer Epidemiol Biomarkers Prev 15:32-38
49. Lorente JA, Valenzuela H, Morote J, Gelabert A (1999) Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients. Eur J Nucl Med 26:625-632 (Pubitemid 29263633)
50. Luftner D, Jozereau D, Schildhauer S, Geppert R, Muller C, Fiolka G, Wernecke KD, Possinger K (2005) PINP as serum marker of metastatic spread to the bone in breast cancer patients. Anticancer Res 25:1491-1499 (Pubitemid 40896754)
51. McCloskey E, Paterson A, Kanis J, Tahtela R, Powles T (2010) Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer. Eur J Cancer 46:558-565
52. Meijer WG, van der Veer E, Jager PL, van der Jagt EJ, Piers BA, Kema IP, de Vries EG, Willemse PH (2003) Bone metastases in carcinoid tumors: clinical features, imaging characteristics, and markers of bone metabolism. J Nucl Med 44:184-191
53. Mejjad O, Le Loet X, Basuyau JP, Menard JF, Jego P, Grisot C, Daragon A, Grosbois B, Euller-Ziegler L, Monconduit M (1996) Osteocalcin is not a marker of progress in multiple myeloma. Le Groupe d'Etude et de Recherche sur le Myelome (GERM). Eur J Haematol 56:30-34 (Pubitemid 26074507)
54. Morena M, Terrier N, Jaussent I, Leray-Moragues H, Chalabi L, Rivory JP, Maurice F, Delcourt C, Cristol JP, Canaud B, Dupuy AM (2006) Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J Am Soc Nephrol 17:262-270
55. Mori K, Ando K, Heymann D, Redini F (2009) Receptor activator of nuclear factor-kappa B ligand (RANKL) stimulates bone-associated tumors through functional RANK expressed on bone-associated cancer cells? Histol Histopathol 24:235-242
56. Narita N, Yuasa T, Tsuchiya N, Kumazawa T, Narita S, Inoue T, Ma Z, Saito M, Horikawa Y, Satoh S, Ogawa O, Habuchi T (2008) A genetic polymorphism of the osteoprotegerin gene is associated with an increased risk of advanced prostate cancer. BMC Cancer 8:224
57. Nguyen TV, Meier C, Center JR, Eisman JA, Seibel MJ (2007) Bone turnover in elderly men: relationships to change in bone mineral density. BMC Musculoskelet Disord 8:13
58. Oremek GM, Weis A, Sapoutzis N, Sauer-Eppel H (2003) Diagnostic value of bone and tumour markers in patients with malignant diseases. Anticancer Res 23:987-990 (Pubitemid 36750908)
59. Osteomark NTX (2008) Accurate answers for osteoporosis patient management: urine ELISA, serum ELISA. http://www.osteomark.com/UEPerformance.cfm
60. Papotti M, Kalebic T, Volante M, Chiusa L, Bacillo E, Cappia S, Lausi P, Novello S, Borasio P, Scagliotti GV (2006) Bone sialoprotein is predictive of bone metastases in resectable non-small-cell lung cancer: a retrospective case-control study. J Clin Oncol 24:4818-4824 (Pubitemid 46630907)
61. Paterson CR, Robins SP, Horobin JM, Preece PE, Cuschieri A (1991) Pyridinium crosslinks as markers of bone resorption in patients with breast cancer. Br J Cancer 64:884-886
62. Pecherstorfer M, Zimmer-Roth I, Schilling T, Woitge HW, Schmidt H, Baumgartner G, Thiebaud D, Ludwig H, Seibel MJ (1995) The diagnostic value of urinary pyridinium cross-links of collagen, serum total alkaline phosphatase, and urinary calcium excretion in neoplastic bone disease. J Clin Endocrinol Metab 80:97-103
63. Pecherstorfer M, Seibel MJ, Woitge HW, Horn E, Schuster J, Neuda J, Sagaster P, Kohn H, Bayer P, Thiebaud D, Ludwig H (1997) Bone resorption in multiple myeloma and in monoclonal gammopathy of undetermined significance: quantification by urinary pyridinium cross-links of collagen. Blood 90:3743-3750 (Pubitemid 27473447)
64. Puistola U, Risteli L, Kauppila A, Knip M, Risteli J (1993) Markers of type I and type III collagen synthesis in serum as indicators of tissue growth during pregnancy. J Clin Endocrinol Metab 77:178-182 (Pubitemid 23206799)
65. Ramankulov A, Lein M, Kristiansen G, Loening SA, Jung K (2007) Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer. Prostate 67:330-340
66. Santini D, Perrone G, Roato I, Godio L, Pantano F, Grasso D, Russo A, Vincenzi B, Fratto ME, Sabbatini R, Della Pepa C, Porta C, Del Conte A, Schiavon G, Berruti A, Tomasino RM, Papotti M, Papapietro N, Onetti Muda A, Denaro V, Tonini G (2011) Expression pattern of receptor activator of NFkappaB (RANK) in a series of primary solid tumors and related bone metastases. J Cell Physiol 226:780-784
67. Sassi ML, Eriksen H, Risteli L, Niemi S, Mansell J, Gowen M, Risteli J (2000) Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: loss of antigenicity by treatment with cathepsin K. Bone 26:367-373 (Pubitemid 30136127)
68. Seibel MJ, Woitge HW, Pecherstorfer M, Karmatschek M, Horn E, Ludwig H, Armbruster FP, Ziegler R (1996) Serum immunoreactive bone sialoprotein as a new marker of bone turnover in metabolic and malignant bone disease. J Clin Endocrinol Metab 81:3289-3294 (Pubitemid 26296204)
69. Shimozuma K, Sonoo H, Fukunaga M, Ichihara K, Aoyama T, Tanaka K (1999) Biochemical markers of bone turnover in breast cancer patients with bone metastases: a preliminary report. Jpn J Clin Oncol 29:16-22
70. Souberbielle JC (2004) Exploration biologique des osteoporoses. Medicine Nucleaire-Imagerie fonctionelle et metabolique 28(2):77-84
71. Teitelbaum SL (2000) Bone resorption by osteoclasts. Science 289:1504-1508
72. Terpos E, Szydlo R, Apperley JF, Hatjiharissi E, Politou M, Meletis J, Viniou N, Yataganas X, Goldman JM, Rahemtulla A (2003) Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 102:1064-1069 (Pubitemid 36917805)
73. Terpos E, Politou M, Szydlo R, Nadal E, Avery S, Olavarria E, Kanfer E, Goldman JM, Apperley JF, Rahemtulla A (2004) Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma. Leukemia 18:1420-1426 (Pubitemid 39136753)
74. Terpos E, Kiagia M, Karapanagiotou EM, Charpidou A, Dilana KD, Nasothimiou E, Harrington KJ, Polyzos A, Syrigos KN (2009) The clinical significance of serum markers of bone turnover in NSCLC patients: surveillance, management and prognostic implications. Anticancer Res 29:1651-1657
75. Thurairaja R, Iles RK, Jefferson K, McFarlane JP, Persad RA (2006) Serum amino-terminal propeptide of type 1 procollagen (P1NP) in prostate cancer: a potential predictor of bone metastases and prognosticator for disease progression and survival. Urol Int 76:67-71 (Pubitemid 43087524)
76. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD Jr (2003) The role of the wnt-signaling antagonist dkk1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349:2483-2494 (Pubitemid 38010074)
77. Tu Q, Zhang J, Fix A, Brewer E, Li YP, Zhang ZY, Chen J (2009) Targeted overexpression of BSP in osteoclasts promotes bone metastasis of breast cancer cells. J Cell Physiol 218:135-145
78. Ulrich U, Rhiem K, Schmolling J, Flaskamp C, Paffenholz I, Salzer H, Bauknecht T, Schlebusch H (2001) Cross-linked type I collagen C-and N-telopeptides in women with bone metastases from breast cancer. Arch Gynecol Obstet 264:186-190 (Pubitemid 32105009)
79. Valverde P, Tu Q, Chen J (2005) BSP and RANKL induce osteoclastogenesis and bone resorption synergistically. J Bone Miner Res 20:1669-1679 (Pubitemid 41243555)
80. Voorzanger-Rousselot N, Juillet F, Mareau E, Zimmermann J, Kalebic T, Garnero P (2006) Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a crossectional and longitudinal evaluation. Br J Cancer 95:506-514 (Pubitemid 44232560)
81. Wada N, Ishii S, Ikeda T, Kitajima M (2004) Inhibition of bone metastasis from breast cancer with pamidronate resulting in reduction of urinary pyridinoline and deoxypyridinoline in a rat model. Breast Cancer 11:282-287
82. Waltregny D, Bellahcene A, Van Riet I, Fisher LW, Young M, Fernandez P, Dewe W, de Leval J, Castronovo V (1998) Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer. J Natl Cancer Inst 90:1000-1008 (Pubitemid 28340442)
83. Waltregny D, Bellahcene A, de Leval X, Florkin B, Weidle U, Castronovo V (2000) Increased expression of bone sialoprotein in bone metastases compared with visceral metastases in human breast and prostate cancers. J Bone Miner Res 15:834-843 (Pubitemid 30233406)
84. Woitge HW, Pecherstorfer M, Horn E, Keck AV, Diel IJ, Bayer P, Ludwig H, Ziegler R, Seibel MJ (2001) Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma. Br J Cancer 84:344-351 (Pubitemid 32154427)
85. Wymenga LF, Groenier K, Schuurman J, Boomsma JH, Elferink RO, Mensink HJ (2001) Pretreatment levels of urinary deoxypyridinoline as a potential marker in patients with prostate cancer with or without bone metastasis. BJU Int 88:231-235 (Pubitemid 32863043)
86. Ylisirnio S, Hoyhtya M, Makitaro R, Paaakko P, Risteli J, Kinnula VL, Turpeenniemi-Hujanen T, Jukkola A (2001) Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer. Clin Cancer Res 7:1633-1637 (Pubitemid 32708629)
87. Zhang JH, Wang J, Tang J, Barnett B, Dickson J, Hahsimoto N, Williams P, Ma W, Zheng W, Yoneda T, Pageau S, Chen J (2004) Bone sialoprotein promotes bone metastasis of a non-bone-seeking clone of human breast cancer cells. Anticancer Res 24:1361-1368 (Pubitemid 38954650)
88. Zhang L, Hou X, Lu S, Rao H, Hou J, Luo R, Huang H, Zhao H, Jian H, Chen Z, Liao M, Wang X (2010) Predictive significance of bone sialoprotein and osteopontin for bone metastases in resected Chinese non-small-cell lung cancer patients: a large cohort retrospective study. Lung Cancer 67:114-119